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ARTICLE OPEN
Injection of embryonic stem cell derived macrophages
ameliorates ﬁbrosis in a murine model of liver injury
Sharmin S. Haideri1, Alison C. McKinnon1, A. Helen Taylor1, Phoebe Kirkwood1, Philip J. Starkey Lewis1, Eoghan O’Duibhir1,
Bertrand Vernay1, Stuart Forbes1 and Lesley M. Forrester 1
Chronic liver injury can be caused by viral hepatitis, alcohol, obesity, and metabolic disorders resulting in ﬁbrosis, hepatic scarring,
and cirrhosis. Novel therapies are urgently required and previous work has demonstrated that treatment with bone marrow derived
macrophages can improve liver regeneration and reduce ﬁbrosis in a murine model of hepatic injury and ﬁbrosis. Here, we describe
a protocol whereby pure populations of therapeutic macrophages can be produced in vitro from murine embryonic stem cells on a
large scale. Embryonic stem cell derived macrophages display comparable morphology and cell surface markers to bone marrow
derived macrophages but our novel imaging technique revealed that their phagocytic index was signiﬁcantly lower. Differences
were also observed in their response to classical induction protocols with embryonic stem cell derived macrophages having a
reduced response to lipopolysaccharide and interferon gamma and an enhanced response to IL4 compared to bone marrow
derived macrophages. When their therapeutic potential was assessed in a murine, carbon tetrachloride-induced injury and ﬁbrosis
model, embryonic stem cell derived macrophages signiﬁcantly reduced the amount of hepatic ﬁbrosis to 50% of controls, down-
regulated the number of ﬁbrogenic myoﬁbroblasts and activated liver progenitor cells. To our knowledge, this is the ﬁrst study that
demonstrates a therapeutic effect of macrophages derived in vitro from pluripotent stem cells in a model of liver injury. We also
found that embryonic stem cell derived macrophages repopulated the Kupffer cell compartment of clodronate-treated mice more
efﬁciently than bone marrow derived macrophages, and expressed comparatively lower levels of Myb and Ccr2, indicating that their
phenotype is more comparable to tissue-resident rather than monocyte-derived macrophages.
npj Regenerative Medicine  (2017) 2:14 ; doi:10.1038/s41536-017-0017-0
INTRODUCTION
The regeneration of tissue after injury or disease involves the
complex interplay between stem cells that are capable of directly
regenerating that organ and a variety of support cells that
constitute their niche. Therapies to promote regeneration involve
both direct cell replacement and the modiﬁcation of the
environment to promote endogenous repair.1
Stem cells in the healthy liver have an enormous capacity for
regeneration but chronic injury induced by viral infection, alcohol
abuse, exposure to toxins and metabolic disorders leads to ﬁbrotic
scaring, cirrhosis and the ultimate failure of that regenerative
process.2 The only treatment available is organ transplantation but
with increasing demand and a limited number of donors, there is
an urgent requirement for alternative therapies. Strategies
involving the transplantation of mature hepatocytes has not been
particularly successful3 indicating that it is also crucial to remodel
and repair the damaged niche. Cellular therapies that aim to have
an anti-ﬁbrotic or pro-regenerative effect have met with some
success. Bone marrow cell transplantation can inﬂuence the
progression and recovery of liver ﬁbrosis with more recent studies
indicating that the monocyte/macrophage lineage is the key cell
mediator of this effect.4, 5 The delivery of bone marrow-derived
macrophages (BMDMs) during carbon tetrachloride (CCl4)-induced
liver injury signiﬁcantly reduced the amount of ﬁbrosis and
improved liver function.5 Also, human macrophages delivered to
an immunocompromised mouse during CCl4-induced liver injury
improved liver function and reduced ﬁbrosis.6 Macrophages aid in
ﬁbrosis resolution via phagocytosis of debris and also by secreting
matrix metalloproteases (MMPs) that break down extracellular
matrix components of scar tissue.7 Depletion of restorative
macrophages during the resolution of ﬁbrosis in mice was shown
to cause a failure in scar remodeling.8
Macrophages are thought to stimulate ductular cells to
proliferate through the secretion of tumor necrosis factor-related
weak inducer of apoptosis (TWEAK).9, 10 These ductular cells may
be associated with ﬁbrosis11 but may contain regenerative hepatic
progenitor cells.12 Therefore macrophages may have therapeutic
potential both by reducing ﬁbrosis and by stimulating liver
regeneration.
Further studies on the molecular mechanisms involved in
macrophage tissue repair requires a strategy, whereby a
consistent supply of cells can be genetically modiﬁed to deplete
key molecular components. Furthermore, although autologous
monocytes are a potential source of regenerative macrophages, a
source that has the potential for an “off the shelf” cell therapy
would be essential for the treatment of acute disease. Combining
the proliferative and differentiation capacity of pluripotent stem
cells (PSCs) and the arsenal of genetic engineering technologies
available for their genetic manipulation provides the necessary
tools to progress. Previous studies have demonstrated that it is
possible to produce macrophages from mouse and human PSCs13, 14
with an in depth RNAseq analysis indicating a broadly similar
transcriptional proﬁle between human monocyte-derived and
iPSC-derived macrophages.15
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We demonstrate that pure populations of macrophages can be
produced from mouse embryonic stem cells (ESCs) in vitro at scale
and that these cells have the capacity for repair in vivo in a murine
model of liver ﬁbrosis. ESC-derived macrophages can be distin-
guished from their bone marrow derived counterparts in
phagocytic activity and in the expression of key functional markers
supporting the recent study suggesting that PSC-derived macro-
phages are developmentally related to tissue resident macro-
phages including Kupffer cells and Langerhans cells.16 We show
that ESC-derived macrophages are able to repopulate the Kupffer
cell compartment of macrophage-depleted livers more efﬁciently
than BMDMs and thus provide an effective strategy to study the
role of tissue resident macrophages in tissue repair.
RESULTS
A comparison of embryonic stem cell derived-macrophages and
bone marrow derived macrophages
We produced macrophages from ESC using our published
method13 and directly compared their phenotype and function
with classic BMDMs, the gold-standard source of primary
macrophages. Brieﬂy, ESC were grown in the presence of CSF-1
and IL-3 to form embryoid bodies (EB). EBs adhere to tissue culture
plastic and release non-adherent macrophage progenitor cells
into the medium. These cells are harvested and plated onto non-
treated Petri dishes in the presence of CSF-1 alone. They give rise
to macrophages that adhere to the plastic and form a monolayer.
Embryonic stem cell derived macrophages (ESDMs) and BMDMs
had a comparable morphology but ESDMs appeared slightly larger
in size than BMDMs (Fig. 1a–c). Flow cytometry analyses revealed
that over 90% of ESDMs were double positive for the macrophage
markers, F4/80 and CD11b, and that cells derived from different
time points during the differentiation process (day 10–20)
demonstrated comparable levels of cell surface marker expression
(Fig. 1e, f). In comparison, the population of BMDMs had a slightly
lower percentage of double positive F4/80 and CD11b cells
indicating BMDMs generated in this protocol were more hetero-
geneous than ESDMs (Fig. 1d and f).
To compare the phagocytic activity of ESDMs and BMDMs, we
developed a novel live imaging assay using the operetta high-
content imaging system (Perkin Elmer) which is fully automated
and thus eliminates operator bias out of imagining and analysis. In
this assay pH-sensitive pHrodoTM Bioparticles were used that only
ﬂuoresce within the acidic intracellular environment (Thermo
Fisher Scientiﬁc). This assay allowed us to quantify amount as well
as rate of uptake of bioparticles in real time. Cells were stained
with a deep red plasma membrane stain and NucBlue Live
ReadyProbes reagent, incubated with pHrodoTM bioparticles and
imaged every 5 min for 2.5 h using the operetta high-content
system (Fig. 1g, h) (see videos in Supplementary Figs S5–7 and
Supplementary Fig. S1). An increase in the number of ﬂuorescing
cells was observed over time in both cell types but the
phagocytosis rate of ESDMs was signiﬁcantly lower than BMDMs
(Fig. 1i). Our previous work using ﬂow cytometry indicated that
there was no signiﬁcant difference in phagocytic activity between
BMDMs and ESDMs whereas this sensitive, real time strategy has
uncovered subtle differences.
ESDMs and BMDMs were primed in vitro to adopt a M1-like or
M2-like phenotype by treating them with lipopolysaccharide (LPS)
and interferon gamma (IFNγ) or IL-4, respectively. As expected,
there was a signiﬁcant increase in nitric oxide (NO) production
upon LPS/IFNγ-stimulation from both BMDM and ESDMs but the
activation level of ESDMs was not as high as BMDMs (Fig. 2a). This
was conﬁrmed by the lower level of expression of M1-related
genes, iNos and Cd86 (Fig. 2b, c) in ESDMs. In contrast, the
response of ESDMs to IL4 was signiﬁcantly higher than BMDMs as
assessed by the increased expression of the M2-related genes,
Arg1 and Fizz1 (Fig. 2d, e). Markers of tissue regeneration such as
Tweak, Mmp12, and Mmp13 were lower in ESDMs compared to
BMDM whereas Mmp9 was expressed at a higher level (Fig. 2f–i).
We used our novel imaging strategy to compare the phagocytic
activity of M1-polarized and M2-polarized ESDM and BMDM. LPS-
IFNγ stimulation reduced and IL4 increased the rate of phagocy-
tosis in both cell types but, ESDMs had a lower rate of
phagocytosis in their stimulated cultures compared to the
equivalent cultures of BMDMs (Fig. 2j, k).
Taken together these data demonstrate that the phenotype of
ESDMs can be modiﬁed in a comparable manner to BMDMs but
subtle differences in the extent of their response to polarization
indicates that they have a less inﬂammatory phenotype.
To extend our work to human studies, we optimized a protocol to
generate macrophages from human induced pluripotent stem cells
(iPSC) based on work published by Cowley et al.17 The human iPSC-
derived macrophages (iPSC-DM) that were generated expressed
both the mature macrophage-speciﬁc cell surface marker 25F9 and
CD11b (Fig. 3b) and did not express the monocyte marker CD93
(Fig. 3a). Human iPSC-DM responded to stimuli as expected: M1-
related genes CD40 and CD80 were upregulated when activated by
LPS-IFNγ, whereas M2-related genes TGM2 and MRC1 gene
expression were elevated in response to IL4 (Fig. 3c–f).
We compared naïve and polarized human iPSC-DM with human
monocyte-derived macrophages (MDM) in our live imaging
phagocytosis assay. Human iPSC-DM followed the same trend as
human MDM, where “naïve” and IL4-treated macrophages were
found to be more phagocytic then LPS-IFNγ-treated macrophages
(Fig. 3g and h). However, reminiscent of our observations in
mouse ESDM, human iPSC-DM phagocytosed less than human
MDM in their “naïve” as well as polarized states indicating that
they have a less inﬂammatory phenotype.
ESDMs as an effective cell therapy in a murine model of liver
ﬁbrosis
We next tested whether ESDMs could have a therapeutic effect in
a murine model of liver injury. Mice were treated with CCl4 twice
weekly for 4 weeks with a proportion being randomly selected
to receive either 10 or 20 × 106 ESDM intravenously at the start of
the second week. Mice were sacriﬁced 21 days after ESDM
injection and livers were processed for immunohistochemistry
(Fig. 4a).
BMDM therapy had previously been shown to ameliorate
ﬁbrosis so we assessed whether ESDMs also had an effect on
hepatic ﬁbrosis using picro sirius red (PSR) stain for hepatic
collagens. When the lower number (10 × 106) of ESDM was used
there was no signiﬁcant effect on the level of ﬁbrosis (Fig. 4b–d)
whereas when twice as many ESDMs were injected, a signiﬁcant
reduction in PSR staining was observed (Fig. 4e–g). A decline in
the number of myoﬁbroblasts is a key event during ﬁbrosis
resolution and we also noted a signiﬁcantly lower number of
αSMA positive myoﬁbroblasts in mice treated with the higher
dose of ESDMs (Fig. 4k–m). Healthy, uninjured livers was also
stained and analyzed (Supplementary Fig. S2).
We observed a signiﬁcantly higher number of hepatic ductular
cells, marked by PanCK staining, in CCl4-injured livers that had
been injected with ESDMs compared to control injured livers
(Fig. 5a–f). The higher number of PanCK-positive cells was evident
in animals receiving both doses of ESDMs replicating an effect
previously observed with BMDMs.9
In conclusion this study demonstrates that ESDMs can be
produced on a large scale and they have the potential to
modulate the effect of liver injury by reducing the density of
myoﬁbroblasts and resultant collagen deposition. It is important
to note that the cell number of ESDM used in these experiments
was 10-fold higher than that used for BMDMs in previous studies
indicating that ESDMs could be less potent than BMDMs in their
Murine model of liver injury
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Fig. 1 Comparison of ESDMs and BMDMs. Stained cytospins of BMDMs (a) and ESDMs (b) with image analyses demonstrating that ESDMs are
larger (c) (Scale bars 30 μM). Flow cytometry analyses of BMDMs (d) and ESDM (e) demonstrating a pure population in ESDMs. Images from live
phagocytosis assay of BMDMs (g) and ESDMs (h) at 0 (I), 50 (II, 100 (III) and 150 (IV) minutes after the addition of Phrodo beads and
quantiﬁcation of rate of phagocytosis using Harmony image analysis software (i) (Scale bars 50 μM). See Supplementary Fig. S1 for details of
the assay. [*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001; n= 3, c Unpaired t-test, f One-way ANOVA with Kruskal-Wallis test, i Two-way
ANOVA with Sidak’s multiple comparison test]
Murine model of liver injury
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Fig. 2 M1 and M2 stimulation of ESDMs and BMDMs. Griess nitric oxide assay of naïve, M1 and M2-stimulated BMDMs and ESDMs (a), and
expression of key markers by qRT-PCR analyses, iNos (b) and Cd86 (c) as markers of M1, Arg1 (d) and Fizz1 (e) as markers of M2 phenotypes, and
Tweak (f), Mmp9 (g), Mmp12 (h), and Mmp13 (i) as markers of tissue remodeling. Quantiﬁcation of phagocytosis of M1-and M2-stimulated
BMDMs (j) and ESDMs (k). [*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001; n= 3 per group, Two-way ANOVA with Tukey’s multiple
comparison test]
Murine model of liver injury
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reparative activity. Based on a large number of experiments using
BMDMs5, 9 we are conﬁdent about the number of BMDMs that are
required to evoke a response but a direct comparison of ESDMs
and BMDMs would have to be performed to verify the differences
in potency.
Do ESDMs have a phenotype comparable to tissue resident
macrophages?
It is widely accepted that haematopoietic cells derived from ESCs
in vitro are more related to the blood cells associated with the
primitive wave of haematopoiesis in the yolk sac during
Fig. 3 Production of macrophages from human PSCs. Macrophage derived from hPSC express both CD11b and 25F9 (b) but not CD93 (a) and
key M1 (c, d) and M2-associated genes (e, f) are upregulated upon stimulation. Assessed using a live imaging phagocytosis assay, naïve and
M2-activated macrophages were more phagocytic than M1-activated macrophages and this was observed for both MDMs (g) and iPSC-DMs
(h). [*p< 0.05, **p< 0.01, ***p< 0.001; n= 3, c–f One-way ANOVA, g, h Two-way ANOVA with Tukey’s multiple comparison test]
Murine model of liver injury
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Fig. 4 The higher dose of ESDMs has an anti-ﬁbrotic effect. Schematic a of injury and macrophage injection of 10 or 20million (m)
macrophages. PSR staining (b–g) and aSMA staining (h–m) of liver sections from CCl4-treated livers that were injected with either 10 million
(10m) or 20 million (20 m) ESDMs. Scale bars 200 μM. [*p< 0.05, n= 5 per group, Unpaired t-test]
Murine model of liver injury
SS Haideri et al.
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development.18 Tissue resident macrophages are known to be
derived from the primitive wave of haematopoiesis, well before
the appearance of haematopoietic stem cells (HSC) in the embryo
and develop in the absence of Myb, an important HSC
transcription factor.19 We considered that the subtle differences
that we observed between murine ESDM and BMDMs could be
related to their source rather than their culture conditions as
suggested in a recent study of human iPSC-DM.16 We conﬁrmed
this by demonstrating that Myb and Ccr2 are expressed at a lower
level in ESDMs compared to BMDMs, whereas Pu.1 was higher
(Fig. 6a–c). Thus if ESDMs are more like tissue resident
macrophages than circulating monocyte-derived cells, we
hypothesized that they would be more efﬁcient at repopulating
the Kupffer cell compartment of the liver following ablation of
endogenous resident macrophages with liposomal clodronate.
We ﬁrst conﬁrmed that liposomal clodronate treatment did
indeed ablate the resident macrophage population and analyzed
the tissue at different time-points to determine the optimal time for
the addition of exogenous macrophages. No F4/80+ macrophages
were observed in liver sections 48 h after liposomal clodronate
treatment indicating that complete depletion had occurred by this
time point. A few F4/80+ macrophages were evident 72 h after
treatment when endogenous circulating macrophages begin to
repopulate the tissue (Supplementary Fig. S3).
ESDM and BMDM were labeled with CFSE cell tracking dye
(Molecular probes, Life Technologies) and 5 × 106 cells were
injected intravenously 48 h after liposomal clodronate treatment
(Fig. 6d). Liver, lung, kidney, and heart tissue was harvested 24 h
later and immunostaining using an anti-FITC antibody (which
detects all derivatives of ﬂuorescein including CFSE) was used to
detect the injected CFSE-stained cells (Fig. 6e–h, Supplementary
Fig. S4). CFSE+ cells were detected in liver sections derived from
liposomal clodronate treated mice that received either BMDM or
ESDM. Quantiﬁcation of images demonstrated that there were
signiﬁcantly more CSFE+ cells in the livers of mice that were
injected with ESDMs compared to BMDMs (Fig. 6m). This result
was conﬁrmed by quantiﬁcation of a DAB-based detection
method to identify CSFE+ cells (Fig. 6i–l, n). Some BMDMs and
ESDMs were also detected in lung tissue but very few cells
engrafted in the kidney and heart of clodronate treated animal.
(Supplementary Fig. S4).
These data indicate that ESDMs have a higher capacity to
repopulate the Kupffer cell compartment than BMDMs which
could suggest that ESDMs have a phenotype more akin to tissue
resident macrophages.
Serum analysis was carried out to assess the effects of the
treatments carried out on liver function of the mice (Fig. 6o, p).
Alkaline phosphatase (ALP) levels were signiﬁcantly elevated in
liposomal clodronate treated mice compared to phosphate
buffered saline (PBS) control mice indicating liver damage. ALP
levels were signiﬁcantly lowered in mice that received ESDM,
compared to controls indicating that ESDMs had some reparative
effect. Serum albumin levels of ESDM recipient mice were also
comparable to healthy controls.
DISCUSSION
We have compared the phenotype and functional properties of
ESDM and BMDM. The activation proﬁle of ESDM indicates that
they are skewed towards an anti-inﬂammatory phenotype.
Unstimulated ESDM had elevated levels of M2-related genes
and they did not mount the same level of response to
inﬂammatory stimuli as BMDM. Our ﬁndings are consistent with
previous publications that demonstrated that ESDM are less
inﬂammatory and more M2-like in comparison to BMDM.20
We developed a live imaging assay to evaluate macrophage
phagocytic ability. This allowed us to monitor not only the number
of particles engulfed at the end, but also the rate at which
Fig. 5 ESDMs can initiate a progenitor response in injured livers. A signiﬁcantly higher number of PanCK-positive cells were observed in mice
injected with ESDMs compared to control injury livers (a–f). Scale bars 100 μM. [*p< 0.05, n= 5 per group, Unpaired t-test]
Murine model of liver injury
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Fig. 6 ESDMs can repopulation the liver of liposomal chlodronate-treated mice. Expression of markers differentially expressed in monocyte-
derived vs. tissue-resident macrophages, Myb (a), Ccr2 (b), and Pu.1 (c). Schematic representation (d) of liposomal clodronate-induced Kupffer
cell depletion and injection of ESDM or BMDM. CFSE immunostaining (e–h Scale bars 100 μM) and CFSE immunohistochemistry (i–l Scale bars
50 μM.) of liver sections from the different treatment groups. Quantiﬁcation of CFSE+ immunostaining (m) and CFSE+ immunohistochemistry
(n). Arrowheads point at CFSE+ cells detected. Blood serum analysis of o Alkaline phosphatase (ALP), and p Albumin levels. [*p< 0.05, **p<
0.01, ***p< 0.001, ****p< 0.0001; n= 5 per group, One-way ANOVA]
Murine model of liver injury
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macrophages phagocytosed the particles. We found that unsti-
mulated ESDM did not phagocytose as fast or as many bioparticles
as BMDM. Furthermore, ESDM and BMDM primed towards the M2-
like phenotype phagocytosed more bioparticles than their M1-
primed equivalents. Our results corroborate with ﬁndings from
previous studies showing that ESDM are less phagocytic than
BMDM.20
Our in vitro characterization lead us to hypothesize that ESDMs
would prove to be more beneﬁcial for ﬁbrosis resolution as they
were skewed towards an anti-inﬂammatory phenotype, and did
not respond as much as BMDMs to inﬂammatory stimuli.
ESDM aids ﬁbrosis regression in a murine model of liver ﬁbrosis
When 20 × 106 ESDM were transplanted, the amount of liver
ﬁbrosis was signiﬁcantly reduced and the number of αSMA +
myoﬁbroblasts was reduced to 50% of control after ESDM delivery.
No signiﬁcant changes were observed in ﬁbrosis or myoﬁbroblast
numbers when 10 × 106 ESDM were transplanted indicating that
this anti-ﬁbrotic effect was dose dependent. Interestingly, like
BMDMs, both high and low doses of ESDMs stimulated a ductular
response as demonstrated by a signiﬁcant increase in PanCK +
progenitors. These data demonstrate that ESDM therapy can aid in
regeneration of damaged liver tissue by inducing the proliferation
of PanCK + ductular cells, and at high dose, ameliorate ﬁbrosis. To
our knowledge, this is the ﬁrst study that demonstrates a
therapeutic effect of ESDMs in a model of liver injury.
The number of ESDMs required to result in a therapeutic effect
was much higher than BMDMs. In a previous study, Thomas et al.
showed that 1 × 106 transplanted BMDMs had a therapeutic effect
during liver ﬁbrosis.5 Whereas in our study 20 × 106 ESDMs were
required to exert a comparable response.
We had found earlier that ESDMs were less phagocytic than
BMDMs in a live imaging phagocytosis assay. This led us to
postulate that ESDMs probably did not phagocytose as much as
BMDMs in vitro and therefore less ﬁbrosis resolution was
observed. And more ESDMs were required to have an effect
comparable to 1 × 106 BMDMs.
ESDM are more efﬁcient at repopulating a Kupffer cell-depleted
liver than BMDM
The above results led us to propose that ESDM may be similar to
tissue resident macrophages instead of MDM as recently
suggested for human iPSC-derived macrophages.16 Studies have
shown that CSF-1 promotes a resident macrophage phenotype
and regulates tissue-resident macrophage numbers.21 In our
study, ESC were differentiated in the presence of CSF-1 to
produce ESDM and it is possible that this promotes a resident
phenotype.
We found that ESDMs expressed lower levels of Myb and Ccr2
and higher expression of Pu.1 than BMDMs, indicating a tissue-
resident macrophage proﬁle. Therefore we assessed the repopula-
tion capacities of ESDM and BMDM in vivo in Kupffer cell depleted
livers to test if ESDM would be more efﬁcient than BMDM in this
experiment. Signiﬁcantly higher numbers of CFSE + transplanted
cells were detected in ESDM recipients compared to BMDM
recipients. These results indicated that ESDM were more efﬁcient
than BMDM at reversing the effects of liposomal clodronate
treatment in mice by partially repopulating the Kupffer cell
compartment. This could either be due to the fact that the
phenotype of ESDMs is more comparable to a tissue resident
macrophage than BMDMs or that they have an enhanced ability to
migrate to the macrophage-depleted tissue.
A study comparing human ESC-derived macrophages (hESC-
DM) (generated in the presence of CSF-1 and IL-3), fetal liver-
derived macrophages and adult monocyte derived macrophages,
showed that hESC-DM and fetal liver macrophages followed a
similar differentiation pathway, distinct from that of MDM. hESC-
DM and fetal liver macrophages were also found to be M2
polarized.22
In conclusion, we were able to produce a homogenous
population of functional macrophages from mouse and human
PSCs. They exhibited characteristic macrophage morphology and
expressed macrophage speciﬁc cell surface markers. When
compared to mouse BMDM and human MDM respectively, they
were found to be less phagocytic and skewed towards an anti-
inﬂammatory phenotype. When mouse ESDM were assessed in a
murine CCl4-induced model of liver ﬁbrosis, they helped in ﬁbrosis
regression, reduced the number of activated myoﬁbroblasts and
induced the proliferation of hepatic ductular cells. However, a
higher number of ESDM were required (compared to BMDM) to
have that effect. When we compared their abilities in repopulating
the resident Kupffer cell compartment in liposomal clodronate
treated livers, ESDM were found to be more efﬁcient than BMDM at
repopulating Kupffer cell-depleted livers, and also signiﬁcantly
improved their liver function. This indicates that murine ESDM
have a phenotype more akin to tissue resident macrophages rather
than circulating monocyte derived macrophages which supports
recent ﬁndings in the human system.16 We show for the ﬁrst time
that macrophages derived from ESC are functionally therapeutic
for chronic liver disease.
As a ﬁrst step towards translating the therapeutic effects of
macrophages in a clinical setting, we optimized a feeder-free and
serum-free protocol to efﬁciently generate macrophages from
human iPSC.
MATERIALS AND METHODS
Mouse ESC maintenance and differentiation
The mouse ESC line E14IV was maintained in Glasgow minimum essential
medium (Gibco) supplemented with 10% fetal calf serum (FCS) (Lonza), 2
mM Sodium pyruvate (Gibco), 4 mM L-glutamine (Gibco), 1% non-essential
amino acids (Gibco) and 0.1 mM β-mercaptoethanol (Sigma) and 100 U/mL
of leukemia inhibitory factor (LIF) as previously described.23 The same
medium (without LIF) supplemented with 15% L929-conditioned media
and 1 ng/mL recombinant IL-3 (Stem Cell Technologies) (herein referred to
as Differentiation medium) was used for the production of macrophage as
described previously (Zhang et al.). Brieﬂy, 6 × 105 ESCs were cultured in
suspension in differentiation medium to form EB. On day 8, EBs were
plated onto gelatinised tissue-culture dishes then non-adherent cells were
harvested from these cultures on alternate days (day 10–20) then plated
onto non-treated bacteriological petri dishes in differentiation medium
without IL-3. These monocyte-like cells adhered to the plastic petri-dishes
forming a monolayer and matured into ESDM.
Bone marrow derived macrophages
Bone marrow was ﬂushed from murine femurs and tibia, cultured in Ultra-
low attachment 25 cm2 ﬂasks (Corning) in Dulbecco’s Modiﬁed Eagle
Medium (DMEM) (Sigma) with 10% FCS, 15% L929-conditioned media and
1% Pen/Strep for 7 days (with a media change on day 4) then BMDM were
harvested by collecting all adherent and non-adherent cells.
Differentiation of human iPSCs to macrophages
The human induced PSCs line, SFCi55 was generated in house and was
conﬁrmed to be pluripotent and have a normal karyotype.24 They were
maintained in StemPro medium prepared by supplementing DMEM/F12
with Glutamax (Invitrogen) with StemPro supplement (Invitrogen), 1.8%
BSA (Invitrogen), 0.1 mM β-mercaptoethanol (Invitrogen) and 20 ng/mL
human basic ﬁbroblast growth factor (Invitrogen). The method for
differentiation of iPSCs to macrophages was adapted from Cowley
et al.17 On Day 0, spent medium was removed from one conﬂuent well
of a 6-well plate, and replaced with 2mL StemPro (ThermoFisher)
supplemented with cytokine Mix 1 (50 ng/mL BMP4, 50 ng/mL VEGF, and
20 ng/mL SCF). Cells were cut using the EZPassageTM tool, and gently
dislodged with a Pasteur pipette. They were divided equally into two wells
of an ulta-low attachment 6-well plate (Corning), and 2mL X-VIVOTM 15
media with cytokine Mix 1 was added to each well. Cells were cultured in
suspension for 3 days with a cytokine top up on Day 2, to make EBs. On
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Day 4, EBs were lifted and transferred to gelatin-coated tissue-culture
grade 6-well plates in X-VIVOTM 15 media supplemented with cytokine Mix
2 (100 ng/mL M-CSF, 25 ng/mL IL3, 2 mM Glutamax, 1% Penicillin/
Streptomycin, 0.055M β-mercaptoethanol). Approximately 30 EBs were
plated in each well. EBs were maintained in this medium for the remaining
duration of the protocol, with spent medium being replaced with fresh
medium every 3–4 days. After about 2 weeks, the EBs produced macro-
phage progenitors in the culture supernatant that were harvested and
transferred to 10 cm2 bacteriological dishes in X-VIVOTM 15 medium
supplemented with cytokine Mix 3 (100 ng/mL M-CSF, 2 mM Glutamax, 1%
Penicillin/Streptomycin) and allowed to mature for 5-7 days into iPSC-DM.
Macrophage progenitors were harvested twice a week for approximately 2
months.
Cytospin and rapid romanowsky staining
Cytospins of macrophages were prepared by harvesting, counting and re-
suspending 1 × 105 macrophages in 200 μL PBS. They were cytocentri-
fuged at 300×g for 3 min in a Thermo Shandon Cytospin 4 and allowed to
air dry. The Rapid Romanowsky Stain Pack (TCS Biosciences) was used to ﬁx
and stain the cells as per manufacturer’s instructions. The slides were
rinsed brieﬂy in water, air-dried and mounted with Mowiol (Sigma).
Macrophage polarization
Adherent ESDM and BMDM were primed in vitro to adopt a M1-like or M2-
like phenotype by treating with LPS (0.1 µg/mL) (Sigma L4391-1 mg) and
IFNγ (10 U/mL) or IL-4 (20 ng/mlL, respectively for 48 h. The Griess Reagent
System (Promega) was used to measure NO− levels in culture supernatants
according to the manufacturer’s instructions.
Flow cytometry
Cells were harvested, counted and 1 × 106 cells were resuspended in 100
μL PBS containing 1% Bovine Serum Albumin (BSA). Pre-conjugated
antibodies were added at their optimal concentrations and incubated on
ice for 20min. Cells were subsequently washed in 2mL PBS (containing 1%
BSA) and centrifuged at 400×g for 5 min. Cell pellets were resuspended in
200 μL PBS with 1% BSA. In most experiments cells were stained with a
live/dead cell viability stain such as DAPI or 7-AAD. The following anti-
mouse antibodies were used: anti-F4/80 APC (BioLegend), anti-CD11b
Alexaﬂuor 488 (BioLegend). The following anti-human antibodies were
used: anti-CD93 PE (eBioscience), anti-25F9 APC (eBioscience), anti-CD11b
Alexaﬂuor 488 (BioLegend).
Quantitative real-time PCR (qRT-PCR)
qRT-PCR was performed using the ABI 7500 Fast Real-Time PCR System
(Applied Biosystems) and analyzed with SDS software Version 1.4 (Applied
Biosystems). The Taqman Fast Universal PCR Master Mix (2×) (Applied
Biosystems) was used with UPL assays that were designed on the Universal
ProbeLibrarySystem Assay Design Center (Roche) (Supplementary Table 1).
The ΔΔCt method was used with GAPDH to normalize cDNA levels and the
“control” sample of each experiment was used as a calibrator to calculate
relative change in gene expression. All data is presented as fold-change
over the expression level of the calibrator.
Phagocytosis assay by live imaging
1 × 105 macrophages were plated in tissue-culture grade 96-well plates
(CellCarrier, PerkinElmer) 3 days prior to imaging. Cells were washed with
PBS, 100 μL NucBlue Live ReadyProbes Reagent (Molecular Probes) (two
drops per 1mL PBS) was added to each well and incubated at 37 °C for 20
min. Cells were washed with PBS and treated with 100 μL/well of
CellMaskTM deep red plasma membrane stain (Molecular Probes) as per
the manufacturer’s instructions and incubated for a further 30min.
CellMaskTM reagent was aspirated and 100 μL PBS was added to each
well. One vial of pHrodoTM Green Zymosan A BioParticles Conjugate
(Molecular Probes) was resuspended in 2 mL PBS at 0.5 mg/mL, thoroughly
vortexed and brieﬂy sonicated then further diluted 1:5 in PBS. 100 μL of
pHrodoTM BioParticles were added to each immediately prior to imaging.
Imaging was performed on the Operetta High-Content Imaging System
(Perkin Elmer) at 5 min intervals, at 40× magniﬁcation, and images were
analyzed on the Harmony High-Content Imaging and Analysis Software
(Perkin Elmer). Each experiment was carried out three times, and included
three technical replicates.
Liver ﬁbrosis model
Liver injury was induced in 8–10-weeks old 129/SV mice (Harlan
Laboratories) by intra-peritoneal injection of 2 μL/g CCl4 (1:3 CCL4:olive
oil) twice a week over a 4-week period. Mice were randomly selected to
receive intravenous injections of ESDMs or control saline (n = 5 per group)
at the start of week two and mice were culled 21 days later. Livers were
perfused with saline, removed and ﬁxed in formalin and processed for
immunohistochemistry.
Liposomal clodronate-mediated Kupffer cell depletion
Liposomal clodronate (5 mg/mL) was purchased from
clodronateliposomes.org. The clodronate suspension was brought to 37 °
C and mixed thoroughly prior to injecting. 200 μL of liposomal clodronate
or control PBS (n = 5 per group) was injected into the tail vein.
Immunohistochemistry
Tissues were embedded in parafﬁn and 4 μm slices were cut and mounted
on glass slides and immunohistochemistry was carried out for detection of
αSMA, PanCK, CFSE and F4/80 as described5, 25 (See Supplementary
Table 2 for antibody details). For PSR staining, sections were dewaxed and
rehydrated. Sections were treated in haematoxylin for 8 min followed by
PSR for an hour. Slides were subsequently washed in acidiﬁed water,
dehydrated and mounted.
For quantiﬁcation of PSR and αSMA staining, images at 40× (Nikon
Eclipse E600 microscope) were tiled and quantiﬁcation of positive staining
was carried out using the image analysis software, ImageJ. For quantiﬁca-
tion of PanCK staining, positive cells were counted from 20 non-
overlapping ﬁelds per sample as described.5
Statistical analysis
Statistical analysis was performed using the GraphPad Prism software
version 6.0c. All data are expressed as mean + standard error of the mean
(SEM). p-values less than 0.05 were considered statistically signiﬁcant (*p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). The following statistical
analyses were used: Unpaired Student’s t-test and ANOVA.
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